Figure 1
Intratumoral immunotherapy is effective in treating early lung cancer due to enhanced CD8 T-cell function. (A) AdV-tk/GCV (n = 8) or Ad.LacZ/GCV (control) (n = 8) was administered intratumorally at Day 11 when TC1 tumors measured ~250 mm3, and volume was recorded. AdV-tk/GCV provided a significant reduction in tumor volume. (B) Ad.IFNα (n = 8) or Ad.LacZ (control) (n = 8) was administered intratumorally at Day 8 when tumors measured ~250 mm3, and volume was recorded. Ad.IFNα provided a significant reduction in tumor volume. (C) CD8 T-cells form mice receiving AdV-tk/GCV were superior in neutralizing fresh tumor cells in vivo when compared to those CD8 T-cells harvested from mice receiving Ad.LacZ/GCV (n = 5 per group). (D) Mice (n = 8 per group) bearing early TC1 tumors were randomized to four treatment groups (i) AdV-tk/GCV, (ii) Ad.LacZ/GCV, (iii)AdV-tk/GCV and CD8 antibodies or (iv) Ad.LacZ/GCV and CD8 antibodies. Growth curves were plotted. Mice receiving CD8 antibodies, regardless of co-treatment, grew rapidly and with similar growth kinetics. * Represents a p < 0.05, ** represents a p < 0.01, shaded bar designates time over which AdV-tk/GCV therapy took place.